Two fluids, one shared purpose — restoring circulating volume — and a procurement mistake that is easy to make: treating human albumin and a crystalloid such as normal saline as if they were interchangeable strengths of the same resuscitation fluid. They are not. Albumin is a colloid, a large protein that holds fluid inside the blood vessels; crystalloids are small-molecule electrolyte solutions that distribute across the entire extracellular space. The clinical and cost consequences of that difference are real, and they belong on the specification, not in the buyer's discretion.
This comparison is written for licensed importers, distributors and tender authorities — the people who have to place the right fluid on the right line with the right approval number. It explains what each fluid is, how they differ, and where albumin genuinely fits, and it ends with a decision guide for the procurement side.
The one-sentence difference
Human albumin is a colloid: a large plasma protein (molecular weight about 66.5 kDa) that, when infused, remains largely within the intravascular space and draws fluid in by oncotic pressure. Crystalloids — normal saline, Ringer's lactate, balanced solutions — are electrolyte solutions whose small molecules distribute freely across the whole extracellular compartment. Albumin expands circulating volume with less total fluid; crystalloids need a larger volume for the same intravascular effect.
Side-by-side comparison
| Dimension | Human albumin | Crystalloid |
|---|---|---|
| Class | Colloid (plasma protein) | Crystalloid (electrolyte solution) |
| Key component | Albumin, fractionated from pooled human plasma | Electrolytes (sodium chloride, Ringer's lactate, etc.) |
| Distribution | Stays mainly intravascular (high oncotic pressure) | Distributes across the extracellular space |
| Volume needed for effect | Smaller infused volume | Larger infused volume |
| Origin | Donor-derived human plasma (manufactured) | Synthetic, mass-produced |
| Relative cost | High | Low |
| Storage | 2–8 °C, protected from light | Room temperature (most) |
| Typical first-line role | Specific indications (hypoalbuminaemia, paracentesis, etc.) | Routine volume replacement |
The storage line is itself a procurement signal: albumin moves in a validated 2–8 °C cold chain, while most crystalloids sit on a room-temperature shelf. That difference ripples through tendering — cold-chain capacity, freight class, and batch-level temperature documentation all attach to the albumin line and not to the saline line.
Why the difference matters at procurement
The distinction shows up in three places the buying side has to get right.
Separate tender lines
Albumin and crystalloids are specified for different clinical situations, and they appear as separate lines in tenders and reimbursement frameworks. They are not interchangeable units of "IV fluid". Merging the lines, or accepting a quotation that substitutes one for the other, places the wrong product against the specification.
Different registration pathways
Albumin is a plasma-derived biological product registered as a drug, with an NMPA approval number, a batch release certificate and a manufacturer-specific dossier. Crystalloids are far simpler, widely available electrolyte preparations. The registration and import documentation for the two lines are unrelated, and the destination-market import licence names the specific product.
Different supply economics
Albumin starts from pooled human plasma — a donor-derived, limited starting material that must be fractionated, virally inactivated and cold-chained. Crystalloids are inexpensive, high-volume manufactured solutions. The cost gap is structural, not a matter of supplier markup, and it should be expected and budgeted, not negotiated away.
When human albumin is actually indicated
The decision belongs to the clinical indication named in the tender, not to a preference for colloid or crystalloid. Albumin is generally reserved for defined situations rather than used as a default resuscitation fluid:
- Hypovolaemia with hypoalbuminaemia, where oncotic pressure support is required.
- Large-volume paracentesis, where albumin reduces circulatory dysfunction after fluid removal.
- Hepatorenal syndrome and related cirrhotic complications, where albumin is part of specific protocols.
- Plasmapheresis and other procedures where a colloid replacement is clinically indicated.
For routine volume replacement, crystalloids remain the first-line fluid in most clinical protocols. Albumin's advantage is specific — a given intravascular expansion with a smaller infused volume, plus oncotic support — not a blanket superiority for resuscitation.
How to decide which line you need
Three questions resolve the specification:
- Does the tender name a specific indication (hypoalbuminaemia, paracentesis, plasmapheresis)? If so, the line is human albumin.
- Is the requirement generic volume replacement? If so, the line is crystalloid, and albumin should not be quoted as a substitute.
- Is the requirement ambiguous? Stop and ask for the indication before quoting — the two fluids are not alternatives, and guessing is how a wrong order is placed.
Where they do overlap is on the procurement process side: both lines need a lawful supplier, a valid approval reference, and a complete document set. For the albumin line, that means a plasma-derived product with its registration dossier in order.
Frequently asked questions
What is the difference between albumin and crystalloids?
Albumin is a colloid — a large plasma protein that stays mainly inside the blood vessels and draws fluid in by oncotic pressure. Crystalloids such as normal saline and Ringer's lactate are electrolyte solutions that distribute freely across the whole extracellular space. Albumin expands circulating volume with less total fluid; crystalloids require larger volumes to achieve the same intravascular effect.
When is human albumin indicated instead of crystalloid?
Albumin is generally reserved for specific indications — hypovolaemia with hypoalbuminaemia, large-volume paracentesis, hepatorenal syndrome, plasmapheresis, or where a colloid is clinically required. For routine volume replacement, crystalloids remain the first-line fluid in most protocols. The indication, not the buyer's preference, decides the line.
Is albumin more effective than saline for resuscitation?
Not universally. Large trials have shown albumin is generally safe but not routinely superior to crystalloids for most resuscitation. Its advantage is specific: it achieves a given intravascular expansion with a smaller infused volume and supports oncotic pressure, which matters in defined clinical settings rather than as a default choice.
Why is albumin more expensive than crystalloid?
Albumin is fractionated from pooled human plasma — a limited, donor-derived starting material that requires purification, viral inactivation and cold-chain handling. Crystalloids are inexpensive manufactured electrolyte solutions. The plasma origin and manufacturing burden explain most of the cost difference.
What strength of human albumin is supplied?
The human albumin supplied under wanyoda's export mandate is presented as a 20% solution in single-dose vials (5 g / 25 ml and 10 g / 50 ml), stored at 2–8 °C protected from light. See the product specification for the full approval reference and presentation.
Where to go next
- Human Albumin 20% — full specification and approval reference for the albumin line.
- Human Albumin 5% vs 20% — how albumin strengths differ, and which presentation fits which indication.
- Documents a Chinese plasma supplier must provide — the document set that proves an albumin consignment is lawful and in-spec.
- Product index — the full plasma-derived portfolio, by manufacturer.